FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026470830> ?p ?o ?g. }

• W2026470830 endingPage "1872" @default.
• W2026470830 startingPage "1870" @default.
• W2026470830 abstract "Background: The characterization of the genes encoding melanoma-associated antigens MART-1 or gp100, recognized by T cells, has opened new possibilitiesfor the development of immunization strategies for patients with metastatic melanoma. With the use of recombinant adenoviruses expressing either MART-1 or gp100 to immunize patients with metastatic melanoma, we evaluated the safety, immunologic, and potential therapeutic aspects of these immunizations. Methods: In phase I studies, 54 patients received escalating doses (between 10 7 and 10 11 plaque-forming units) of recombinant adenovirus encoding either MART-1 or gp100 melanoma antigen administered either alone or followed by the administration of interleukin 2 (IL-2). The immunologic impact of these immunizations on the development of cellular and antibody reactivity was assayed. Results: Recombinant adenoviruses expressing MART-1 or gp100 were safely administered. One of 16 patients with metastatic melanoma receiving the recombinant adenovirus MART-1 alone experienced a complete response. Other patients achieved objective responses, but they had received IL-2 along with an adenovirus, and their responses could be attributed to the cytokine. Immunologic assays showed noconsistent immunization to the MART-1 or gp100 transgenes expressed by the recombinant adenoviruses. High levels of neutralizing anti-body were found in the pretreatment sera of the patients. Conclusions: High doses of recombinant adenoviruses could be safely administered to cancer patients. High levels of neutralizing anti-body present in patients' sera prior to treatment may have impaired the ability of these viruses to immunize patients against melanoma antigens." @default.
• W2026470830 created "2016-06-24" @default.
• W2026470830 creator A5021773274 @default.
• W2026470830 creator A5023499404 @default.
• W2026470830 creator A5033155015 @default.
• W2026470830 creator A5033167690 @default.
• W2026470830 creator A5033798832 @default.
• W2026470830 creator A5052980036 @default.
• W2026470830 creator A5055074037 @default.
• W2026470830 creator A5059941996 @default.
• W2026470830 creator A5071835245 @default.
• W2026470830 creator A5072133376 @default.
• W2026470830 creator A5080668581 @default.
• W2026470830 creator A5085899790 @default.
• W2026470830 date "1998-12-16" @default.
• W2026470830 modified "2023-10-13" @default.
• W2026470830 title "Immunizing Patients With Metastatic Melanoma Using Recombinant Adenoviruses Encoding MART-1 or gp100 Melanoma Antigens" @default.
• W2026470830 cites W114318986 @default.
• W2026470830 cites W1489827712 @default.
• W2026470830 cites W1494409817 @default.
• W2026470830 cites W1524716693 @default.
• W2026470830 cites W1529660394 @default.
• W2026470830 cites W1535342352 @default.
• W2026470830 cites W1543077929 @default.
• W2026470830 cites W1588193878 @default.
• W2026470830 cites W1965164421 @default.
• W2026470830 cites W1966584188 @default.
• W2026470830 cites W1967884480 @default.
• W2026470830 cites W1983806918 @default.
• W2026470830 cites W1986046751 @default.
• W2026470830 cites W1989669523 @default.
• W2026470830 cites W1991051335 @default.
• W2026470830 cites W1992847016 @default.
• W2026470830 cites W2014649439 @default.
• W2026470830 cites W2015617337 @default.
• W2026470830 cites W2019378981 @default.
• W2026470830 cites W2020301682 @default.
• W2026470830 cites W2046782578 @default.
• W2026470830 cites W2051221638 @default.
• W2026470830 cites W2062144971 @default.
• W2026470830 cites W2065459476 @default.
• W2026470830 cites W2067157368 @default.
• W2026470830 cites W2068831259 @default.
• W2026470830 cites W2076845203 @default.
• W2026470830 cites W2079791074 @default.
• W2026470830 cites W2088849552 @default.
• W2026470830 cites W2092816252 @default.
• W2026470830 cites W2100240533 @default.
• W2026470830 cites W2116293732 @default.
• W2026470830 cites W2124446900 @default.
• W2026470830 cites W2130185552 @default.
• W2026470830 cites W2146600597 @default.
• W2026470830 cites W2147103876 @default.
• W2026470830 cites W2151902657 @default.
• W2026470830 cites W2168225085 @default.
• W2026470830 cites W2189898826 @default.
• W2026470830 cites W2335365056 @default.
• W2026470830 cites W2403288307 @default.
• W2026470830 cites W2407345953 @default.
• W2026470830 cites W2409525228 @default.
• W2026470830 cites W2411032233 @default.
• W2026470830 cites W2415035478 @default.
• W2026470830 cites W2419332336 @default.
• W2026470830 doi "https://doi.org/10.1093/jnci/90.24.1894" @default.
• W2026470830 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2249697" @default.
• W2026470830 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9862627" @default.
• W2026470830 hasPublicationYear "1998" @default.
• W2026470830 type Work @default.
• W2026470830 sameAs 2026470830 @default.
• W2026470830 citedByCount "289" @default.
• W2026470830 countsByYear W20264708302012 @default.
• W2026470830 countsByYear W20264708302013 @default.
• W2026470830 countsByYear W20264708302014 @default.
• W2026470830 countsByYear W20264708302015 @default.
• W2026470830 countsByYear W20264708302016 @default.
• W2026470830 countsByYear W20264708302017 @default.
• W2026470830 countsByYear W20264708302018 @default.
• W2026470830 countsByYear W20264708302019 @default.
• W2026470830 countsByYear W20264708302020 @default.
• W2026470830 countsByYear W20264708302021 @default.
• W2026470830 countsByYear W20264708302022 @default.
• W2026470830 crossrefType "journal-article" @default.
• W2026470830 hasAuthorship W2026470830A5021773274 @default.
• W2026470830 hasAuthorship W2026470830A5023499404 @default.
• W2026470830 hasAuthorship W2026470830A5033155015 @default.
• W2026470830 hasAuthorship W2026470830A5033167690 @default.
• W2026470830 hasAuthorship W2026470830A5033798832 @default.
• W2026470830 hasAuthorship W2026470830A5052980036 @default.
• W2026470830 hasAuthorship W2026470830A5055074037 @default.
• W2026470830 hasAuthorship W2026470830A5059941996 @default.
• W2026470830 hasAuthorship W2026470830A5071835245 @default.
• W2026470830 hasAuthorship W2026470830A5072133376 @default.
• W2026470830 hasAuthorship W2026470830A5080668581 @default.
• W2026470830 hasAuthorship W2026470830A5085899790 @default.
• W2026470830 hasBestOaLocation W20264708301 @default.
• W2026470830 hasConcept C104317684 @default.
• W2026470830 hasConcept C147483822 @default.
• W2026470830 hasConcept C159047783 @default.

• next